ArticleMaterials today. Bio2025
Engineering a targeted daphnetin delivery system to enhance spinal cord injury treatment effectiveness.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- ROS-responsive hydrogel delivering liposomal indole-3-propionic acid promotes spinal cord injury repair by enhancing CX3CL1-CX3CR1 mediated neuron-microglia communication.Materials today. Bio · 2026Article
- Decoding the molecular mechanisms of pyroptosis and its therapeutic development prospects.Frontiers in cell and developmental biology · 2026Review
- Targeting glial scar formation for spinal cord injury: mechanisms, strategies, and research progress review.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a severe central nervous system disorder characterized by complex neuroinflammatory responses. While natural compounds such as daphnetin have demonstrated anti-inflammatory and neuroprotective effects, their clinical application is hindered by low bioavailability. To address this limitation, we developed a biofabricated nanoliposomal drug delivery system, designed to enhance daphnetin's targeted delivery to macrophages and improve its therapeutic efficacy in SCI repair. A biofabrication-driven approach was employed to synthesize and optimize targeted liposomal nanocarriers (Da@Lip-CRV) using phospholipid-based vesicles conjugated with CRVLRSGSC peptides for macrophage specificity. Their targeting and therapeutic efficiency were evaluated in vitro and in vivo. The biofabricated liposomal system exhibited stable physicochemical properties and enhanced macrophage targeting efficiency. Transcriptomic analyses revealed that Da@Lip-CRV suppressed NF-κB-mediated inflammation, inhibited macrophage pyroptosis, and promoted M2 polarization, thereby facilitating an anti-inflammatory microenvironment conducive to neural repair. Da@Lip-CRV showed superior recovery of hindlimb function, reduced glial scarring, and improved neuronal survival in vivo. This study presents a biofabrication-based liposomal drug delivery platform for targeted SCI therapy. The findings demonstrated that optimize targeted liposomal nanocarriers (Da@Lip-CRV) regulated macrophage polarization and inhibited the pyroptosis of macrophage so as to provide a promising strategy for the clinical treatment of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.